Abstract：
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Conventional methods of UM treatment are based on chemotherapy and radiotherapy, which have been able to control tumor growth in a limited way. But due to the inadequacy and many side effects of these treatments, many UM patients die during treatment, and approximately 50% of patients develop metastasis. Meanwhile, the 2-year survival rate of these patients from the time of metastasis is 8%. Since immunotherapy has the potential to be the most specific and efficient method in the treatment of tumors, it is considered an attractive and promising research field in the treatment of UM. This review highlights recent advances in UM immunotherapy and provides new immunological approaches on how to overcome the challenges of UM immunotherapy.
摘要：
葡萄膜黑色素瘤（UM）是成人最常见的原发性眼内恶性肿瘤。常规的UM治疗方法以化疗和放疗为主,能够以有限的方式控制肿瘤生长。但是由于这些治疗方法的不足和许多副作用，许多UM患者在治疗期间死亡，大约50%的患者发生转移。同时,从转移开始，这些患者的2年生存率为8％。由于免疫疗法有可能成为治疗肿瘤的最具体和最有效的方法，它被认为是治疗UM的一个有吸引力和有前途的研究领域。本文综述了UM免疫治疗的最新进展，并为如何克服UM免疫治疗的挑战提供了新的免疫学方法。
